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622Unpredictability of Intravenous Busulfan
Pharmacokinetics in Children Undergoing
Hematopoietic Stem Cell Transplantation for Advanced
Beta Thalassemia: Limited Toxicity with a
Dose-Adjustment Policy
Robert Chiesa,1,2 Barbara Cappelli,1,2 Roberto Crocchiolo,3,4 Ilaria Frugnoli,1 Erika Biral,1,2
Anna Noe`,1 Costanza Evangelio,1 Marco Fossati,1 Tito Roccia,1 Alessandra Biffi,1,2
Valentina Finizio,1 Alessandro Aiuti,1,2 Monica Broglia,5 Antonella Bartoli,5 Fabio Ciceri,3
Maria Grazia Roncarolo,1,2,6 Sarah Marktel1,2b-thalassemia is a major health problem worldwide, and stem cell transplantation (SCT) is the only curative
option. Oral Busulfan (Bu) based conditioning is widely used in this setting. Due to the variability of Bu sys-
temic exposure, intravenous (i.v.) Bu has been proposed as a standard of care, with no need for drug mon-
itoring and dose adjustment. Patients with b-thalassemia from countries with limited resources might be at
higher risk of erratic Bu metabolism because of liver dysfunction, severe iron overload, and specific ethnic/
genetic features. We studied Bu pharmacokinetics in 53 children with advanced b-thalassemia from Middle
Eastern countries who underwent a total of 57 matched related donor SCTs. Forty-two percent of the chil-
dren required dose adjustment because they did not achieve the therapeutic window after the first dose.
With a Bu dose-adjustment policy, regimen-related toxicity was limited. At a median follow-up of 564
days, the probabilities of 2-year survival, current thalassemia-free survival, rejection, and treatment-related
mortality were 96%, 88%, 21%, and 4%, respectively. Conditioning with i.v. Bu and dose adjustment is feasible
and well tolerated, although recurrence of thalassemia remains an unsolved problem in children with
advanced disease.
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6/j.bbmt.2009.11.024with the highest rates in the Mediterranean, Middle
East and South Asia [1]. The prognosis for b-thalasse-
mia with conventional therapy has improved dramati-
cally, and most children now reach adulthood with an
open-ended survival. Nevertheless, endocrine, cardiac,
and hepatic complications of iron overload still occur,
affecting quality of life and representing the principal
causes of death [2]. Children living in countries with
limited resources may have impaired access to safe
blood products and iron-chelating drugs, leading to
a life expectancy of \20 years [1]. However, in the
risk/benefit balance between stem cell transplantation
(SCT) and medical care, severely ill patients with or-
gan dysfunction also are at greater risk for regimen-
related toxicity (RRT) [3].
Busulfan (Bu) is an ablative alkylating agent used in
conditioning regimens for b-thalassemia, mainly in
concert with cyclophosphamide (Cy) [4]. The use of
oral Bu in the pediatric population is characterized
by extensive absorption variations, with wide interpa-
tient and intrapatient variability in systemic exposure,
Table 1. Patient Characteristics at Transplantation
n %
Number of patients 53 100
Sex, male/female 29/24 55/45
Age, years
Median 8
Range 2-17
Country of origin
Iraq 19 36
Lebanon 9 17
Syria 21 40
Palestinian territories 3 5
Other 1 2
Pesaro class
at time of SCT
Class I 2 4
Class II 26 49
Class III 25 47
Splenectomy, yes/no 12/41 23/77
Iron chelation, regular/irregular 9/44 17/83
Number of pretransplantation
red blood cell units
Median 76
Range 15-230
Serum ferritin, mg/L
Median 3267
Range 956-14.280
Liver iron concentration, mg/g dry
weight*
Median 24
Range 4-95.7
Ishak grading
(portal fibrosis, range 1-6)
Median 3
Range 1-5
AST, U/L
Median 58
Range 18-371
ALT, U/L
Median 72
Range 12-545
HCV antibody–positive, yes/no 15/38 28/72
Anti HLA antibodies
Pesaro class I-II 16 57
Pesaro class III 25 100
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for Advanced b-thalassemiaresulting in overexposure (eg, veno-occlusive disease
[VOD], mucositis) or underexposure (eg, graft rejec-
tion) [5]. Intravenous (i.v.) Bu (Busilvex) has been
introduced for clinical use with a new body weight–
based dose calculation in children [6]. In a pediatric
population affected mostly by malignancies, the new
i.v. dosing regimen has preliminarily demonstrated
a successful target of the therapeutic area under the
plasma concentration versus time curve (AUC) range
of 900-1500 mmol*min, resulting in efficient engraft-
ment and mild to moderate nonhematologic toxicity
[7]. Consequently, the fixed i.v. Bu dosing for pediatric
patients has been proposed as standard practice before
SCT, with no need for drug monitoring and dose ad-
justment. However, recent reports have described vari-
able pharmacokinetics (PK) of i.v. Bu in heterogeneous
groups of children undergoing SCT [8-10], suggesting
that the PK of i.v. Bu might be influenced by age, co-
morbidities, genetic background, and underlying dis-
ease.
We postulated that children with advanced
b-thalassemia could be at greater risk of erratic Bu
metabolism with increased RRT because of organ dys-
function resulting from severe iron overload, infec-
tious diseases, and ethnic/genetic specific features.
Consequently, we conducted a prospective i.v. Bu
PK study in a large, homogeneous group of children
with b-thalassemia fromMiddle Eastern countries un-
dergoing SCT from a matched family donor. The aim
of this study was to evaluate the reliability of standard
i.v Bu fixed dosing in achieving the therapeutic AUC.
In addition, we analyzed the impact of patients’ pre-
transplantation clinical and laboratory features on i.v.
Bu PK and the association between Bu PK and trans-
plantation outcomes, such as overall survival (OS), dis-
ease-free survival (DFS), engraftment and RRT.SCT indicates stem cell transplantation; AST, aspartate aminotransfer-
ase; ALT, alanine aminotransferase; HCV, hepatitis C virus.
*Data available for only 40 patients.PATIENTS AND METHODS
Patient Characteristics
Fifty-four children with b-thalassemia major or
transfusion-dependent thalassemia intermedia were re-
ferred to our institution from Mediterranean and Mid-
dle Eastern countries to undergo SCT. The cost of
treatment was borne by a cooperative program funded
by the Mediterranean Institute of Haematology
(www.fondazioneime.org). In an intention-to-treat
analysis, 1 patient with b-thalassemia intermedia was
not enrolled to SCT because transfusion independency
was achieved after splenectomy. Between December
2005, and September 2008, 53 consecutive children un-
derwent 57 i.v. Bu-conditioned SCTs from a matched
related donor and were included in this analysis. Patient
characteristics are summarized in Table 1. All patients
were assigned to 1 of 3 risk classes proposed byLucarelli
et al. [11] based on hepatomegaly, portal fibrosis in pre-SCT liver biopsy and quality of chelation. The 53
treated patients included 2 patients in risk class I, 26 pa-
tients in risk class II, and25patients in risk class III.Most
patients had severe iron overload, as evidenced by a me-
dian serum ferritin level of 3.267 mg/L (range, 956-
14.280 mg/L) and a median liver iron concentration of
24 mg/g dry weight (range, 4-95.7 mg/g). The median
portal fibrosis score (Ishak score 1-6) was 3 (range, 1-
5); 3 patients (5%) exhibited early signs of liver cirrhosis.
Fifteen patients (28%) had positive antibodies for hepa-
titis C virus (HCV).
Before SCT, all patients received a comprehensive
pretransplantation workup and underwent intensive
iron chelation therapywithdeferoxamine. Splenectomy
was performed in 12 of the 53 patients (23%) because
of splenomegaly below the umbilicus and the conse-
quent risk of poor graft function posttransplantation.
624 Biol Blood Marrow Transplant 16:622-628, 2010R. Chiesa et al.Written informed consent was obtained from each
patient’s parent or legal guardian, with the collabora-
tion of 2 mother language (Arabic and Kurdish) non-
official translators employed full time to fulfill
patients’ and families’ needs.Transplantation Procedures
Fifty-one patients received a transplant from an
HLA-identical sibling, and 2 patients received
a transplant from a phenotypically identical mother.
Thirty-two donors (60%) were heterozygous for b-
thalassemia. Four patients with graft failure underwent
a second SCT from the same donor. Forty patient–
donor pairs were ABO-compatible, 6 had major ABO
incompatibility, 6 had minor ABO incompatibility,
and 1 had bidirectional ABO incompatibility. Fresh
bone marrow (BM) provided the stem cell source for
all patients. The median number of infused BM nucle-
ated cells was 5 108/kg (range 1.4-11.5 108/kg),
that of CD341 cells was 7.7 106/kg (range 3.3-
21.7 106/kg), and that of CD31 cells was 73 106/
kg (range, 23-126 106/kg). The conditioning regi-
men for patients in risk class I-II consisted of i.v. Bu
(detailed below) and Cy 200 mg/kg total dose (on
days 25 to 22) in patients aged $4 years, with thio-
tepa (TT) 10 mg/kg (on day 26) added for patients
aged\4 years. Pretransplantation chemotherapy for
risk class III patients consisted of a ‘‘preconditioning’’
regimen [12] with hydroxyurea 30 mg/kg daily and
azathioprine 3 mg/kg daily (on days245 to211), fol-
lowed by fludarabine (Flu) 100 mg/m2 total dose (on
days 217 to 213), i.v. Bu, and Cy 160 mg/kg total
dose (on days 25 to 22). Because of the occurrence
of 3 graft failures in the first 6 patients in class III,
the immunosuppression in risk class III patients was
strengthened with a higher dose of Flu (150 mg/m2)
and the addition of rabbit antithymocyte globulin
(ATG; Thymoglobulin) 7.5-10 mg/kg total dose (on
days27 to24). Patients undergoing a second SCT re-
ceived a standard preconditioning regimen, followed
by i.v. Bu, Cy 200 mg/kg, TT 10 mg/kg, and ATG
8-12.5 mg/kg [13]. Graft-versus-host disease
(GVHD) prophylaxis consisted of oral cyclosporine
(CsA) adjusted to a trough plasma level of 150-250
ng/mL. In the absence of GVHD, CsA was tapered
from day 60 until discontinuation at 1 year. All patients
received a short course of i.v. methotrexate (MTX)
10 mg/m2 on days 1, 3, and 6. Additional GVHD pro-
phylaxis consisted of methylprednisolone 0.5 mg/kg
from day -1 to day 25 in 33 patients, ATG in 19 pa-
tients, and methylprednisolone plus ATG in 5 pa-
tients. Supportive therapy consisted of ceftriaxone
during neutropenia, acyclovir during neutropenia
and immunosuppression and prophylactic liposomal
amphotericin B 1 mg/kg daily from day 8 until the
lymphocyte count exceeded 1 109/L. A preemptiveapproach with twice-weekly polymerase chain reaction
(PCR) monitoring was adopted for cytomegalovirus
(CMV) treatment, and no prophylaxis was given. Sei-
zure prophylaxis consisted of oral clonazepam starting
24 hours before the first i.v. Bu dose and continuing up
to 24 hours after the last dose. VOD prophylaxis con-
sisted of defibrotide from day 211 to day 30.
Engraftment was defined as the first of 3 consecu-
tive days with an absolute neutrophil count (ANC) of
.0.5 109/L and an unsupported platelet count of
.20 109/L. Engraftment was monitored by short
tandem repeat variability testing on peripheral blood
(PB) and BM. Mixed chimerism was defined as the
presence of recipient DNA .5%. GVHD was graded
according to the criteria of the Seattle group. RRTwas
evaluated using the National Cancer Institute’s com-
mon toxicity criteria (NCI CTC); the overall score
was assigned on signs and symptoms recorded during
the first 100 days after SCT.
Intravenous Bu Administration,
Pharmacokinetics Studies and Bu
Dose-Adjustment Policy
According to the standard [6], 5 different i.v. Bu
doses were given based on weight: 1.0 mg/kg for
\9 kg, 1.2 mg/kg for 9-16 kg, 1.1 mg/kg for 16-23 kg,
0.95 mg/kg for 23-34 kg, and 0.8 mg/kg for .34 kg.
Bu was administered as a 2-hour i.v. infusion every
6 hours for a total of 16 doses from day 29 to day
26. Bu concentrations in plasma were measured by
a validated high-performance liquid chromatography
(HPLC) assay involving protein precipitation, precol-
umn derivatization, liquid/liquid extraction, and ultra-
violet detection [14]. Calculation of the total AUC0-N
was based on PB samples at 0, 2, 3, 4, and 6 hours of
the first dose (AUC0-6 by trapezoidal rule and AUC6-N
by extrapolation to infinity). The prediction of AUC0-6
during the dosing interval at steady state was based on
the equality of the total AUC after the first dose and
the AUC during the dosing interval at steady state after
multiple doses. The reliability of a national reference
pharmacology laboratory allowed us to apply a limited
sampling strategy as preferred by others [15]. Bu AUC
values.900 mmol*min and\1500mmol/minwere con-
sidered to lie within the therapeutic window. The Bu
dose was adjusted fromdose 4 using the following equa-
tion: adjusted dose 5 actual dose  target AUC/actual
AUC (target AUC5 1250 mmol*min). This dose was
used for the remaining course of therapy.
Statistical Analyses
Numerical values are expressed as median and
range, and categorical values are expressed as propor-
tion and percentage. The c2 test (for categorical
variables) and logistic regression (for continuous
variables) were used to explore for any correlation
Table 2. Severe RRT (NCI CTCGrade III-IV) in Patients with
Class I-II and Class III Thalassemia
Class I-II (n5 28) Class III (n5 29) Overall (n5 57)
Infections 17 (60%) 21 (72%) 38 (66%)
Bladder 1 (3%) 4 (14%) 5 (9%)
Pulmonary 1 (3%) 3 (10%) 4 (7%)
Neurologic 1 (3%) 2 (7%) 3 (5%)
Stomatitis 0 2 (7%) 2 (3%)
Renal failure 0 2 (7%) 2 (3%)
Liver (VOD) 0 1 (3%) 1 (2%)
Multiorgan failure 0 1 (3%)* 1 (2%)
Diarrhea 0 0 0
RRT indicates regimen related toxicity; NCI CTC, National Cancer
Institute’s common toxicity criteria; VOD, veno-occlusive disease.
*This patient died due to multiorgan failure after primary graft failure
without autologous reconstitution.
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for Advanced b-thalassemiabetween pretransplantation patient characteristics (ie,
Pesaro class, serum ferritin, Ishak staging, serum ala-
nine aminotransferase [ALT] and aspartate amino-
transferase [AST], HCV infection, age, and sex) and
Bu AUC range (in range vs out of range). Comparisons
of Bu AUC between SCTs with NCI CTC grade III-
IV toxicity and uncomplicated SCTs were done using
theMann-WhitneyU test. OSwas defined as the prob-
ability of survival regardless of disease status, and DFS
was defined as the probability of being alive and dis-
ease-free. Both OS andDFS were estimated by the Ka-
plan-Meier method, and comparisons among groups
were made using the log-rank test. Current DFS also
was evaluated, including patients who were in subse-
quent remission after treatment for graft rejection.
Treatment-related mortality (TRM) was defined as
death from a complication of transplantation. The
incidences of TRM and both acute and chronic
GVHD (aGVHD, cGVHD)were calculated for evalu-
able SCTs by estimating cumulative incidence. All
outcomes were evaluated from the day of stem cell
infusion, and actuarial estimates (with 95% confidence
intervals [CIs]) were calculated at 2 years after SCT.
Patients who underwent a second SCT were censored
at the day of documented graft failure. A P value\.05
was considered statistically significant.RESULTS
Bu Pharmacokinetic Studies
All patients received the full 16-dose course of i.v.
Bu. The median Bu AUC of the whole population (53
SCTs) after the first dose was 1083 mmol*min (range,
669-2698 mmol*min). PK studies following the first
i.v. Bu dose showed that 31 patients (58%) achieved
an AUC within the therapeutic window (900-1500
mmol*min), 13 patients (25%) had an AUC below the
lower target limit, and 9 patients (17%) had an AUC
above the upper target limit. No difference in AUC
was found between class I-II patients and class III
patients (P5 .96). Although the numbers are small,
intrapatient Bu AUC variability was high. In the 4
patients receiving i.v. Bu–based conditioning follow-
ing rejection of the first SCT, Bu AUCs following
the first and second exposures to Bu were 1461/1391,
1237/1106, 1959/1085, and 1798/1019 mmol*min,
respectively.Bu Pharmacokinetics and Pretransplantation
Characterstics
No significant correlation was found between a Bu
AUC outside the therapeutic window and specific pre-
transplantation clinical features. This indicates that
Pesaro risk stratification, serum ferritin, liver fibrosis,
ALT and AST, HCV infection, age, and sex are notassociated with an unfavorable Bu systemic exposure
if a dose-adjustment policy is adopted.
Bu PK and RRT
Table 2 summarizes grade III-IV RRT in the study
population. Notably, 37 patients (66%) developed 41
episodes of severe infection, represented by culture
negative febrile neutropenia (n5 24), Staphylococcus
non-aureus sepsis (n5 6), Pseudomonas aeruginosa sepsis
(n5 3), vancomycin-resistant Enterococcus faecium
(n5 1), Klebsiella spp sepsis (n5 1), BK virus hemor-
rhagic cystitis (n5 5), and severe Pseudomonas aerugi-
nosa vulvovaginitis (n5 1). None of these infections
was fatal. Five patients (9%) experienced moderate to
severe hemorrhagic cystitis, and 2 patients (3%) devel-
oped secondary obstructive renal failure that resolved
after surgery. Four patients (7%) presented with grade
III-IV pulmonary complications with acute respiratory
distress at 15-52 days, which was treated successfully
with noninvasive ventilation. Three patients (5%) ex-
perienced CsA-related posterior reversible encepha-
lopathy syndrome. The incidences of stomatitis (3%)
and VOD (2%) were low. Seven patients developed
grade II-IV aGVHD, with a cumulative incidence of
13% (95% CI5 4%-22%). All were treated success-
fully, except for 1 patient who died at day 56 of grade
IV aGVHDnot responsive to several lines of immuno-
suppression (ie steroids, ATG, etanercept, and infu-
sion of third-party mesenchymal stem cells). Four
patients developed limited cGVHD, with a cumulative
incidence of 8% (95% CI5 1%-15%). Three patients
evolved from aGVHD, and 1 patient developed viti-
ligo as a sole de novo expression of cGVHD. Only 1
of the patients with cGVHD was receiving immuno-
suppressive treatment at the last follow-up. We found
no correlation between the severity of adverse events
after transplantation and Bu AUC after the first dose
(P5 .57). With the exception of the patient who expe-
rienced hepatic VOD 11 days after SCT, none of the
other patients with grade III-IV RRT had a Bu AUC
.1500 mmol*min (Figure 1).
Figure 1. Boxplot of Bu AUC values in 53 thalassemic children with or without grade III-IV toxicity. Outliers are represented as circles (\3 box lengths)
or asterisks (.3 box lengths).
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Fifty patients (94%) engrafted, and 3 patients
(6%) experienced primary graft failure. Of these 3 pa-
tients, 2 had autologous reconstitution and 1 died in
aplasia at day 67. Among the patients who engrafted,
the median time to neutrophil engraftment was 19
days (range, 12-39 days), and the median time to plate-
let engraftment was 18 days (range, 12-73 days). Time
to red cell transfusion independence differed in recip-
ients of first SCT (median, 22 days; range, 0-336 days)
and recipients of a second SCT (median, 90 days;
range, 0-216 days).
Two-year OS at a median follow-up of 564 days
(range, 123-1144 days) was 96% (51 of 53 patients).
One patient died of grade IV aGVHD on day 56,
and 1 patient died of primary graft failure, as discussed
earlier. Secondary graft failure occurred in 5 patients
(9%) and was always followed by autologous reconsti-
tution. We found no correlation between the inci-
dence of graft failure and low Bu systemic exposure
following the institution of the dose-adjustment pol-
icy; in fact, none of the 8 patients who experienced pri-
mary or secondary graft failure had a Bu AUC below
the lower target limit of 900 mmol*min. Graft failure
(primary or secondary) occurred mainly in class III pa-
tients, with only 1 occurring (in the phenoidentical re-
cipient) in class I-II patients and 7 occurring in class III
patients (P5 .02, c2 test). Four of the 8 patients who
experienced graft failure underwent retransplantationfrom the same donor, with a median interval between
the 2 procedures of 12 months (range, 7-16 months).
After the second SCT, all patients engrafted with sus-
tained full donor chimerism. Considering all patients,
chimerism at the last follow-up was 100% donor in 46
patients (87%), 0% donor in 4 patients (7%), and
mixed in 3 patients (6%). Outcomes estimated by
Kaplan-Meier probability were OS, 96% (95%
CI5 91%-100%); DFS, 79% (95% CI5 67%-
91%); current DFS accounting for second SCT,
88% (95% CI5 78%-98%); rejection, 21% (95%
CI5 9%-33%); and TRM, 4% (95% CI5 0-9%).
Transplantation outcome was strongly influenced by
the Pesaro risk class stratification; the class III patients
had an estimated OS of 96% (95% CI5 88%-100%),
an estimated DFS of 66% (95% CI5 45%-87%), and
a current DFS of 85% (95% CI5 69%-100%)
(Figure 2), whereas the class I-II patients had an
OS of 96% (95% CI5 89%-100%) and a DFS of
91% (95% CI5 80%-100%; P5 .04 for DFS)
(Figure 3).DISCUSSION
Our results demonstrate that standard i.v. Bu fixed
dosing in children with advanced b-thalassemia results
in unpredictable systemic exposure requiring a dose-
adjustment policy. In fact, only 58% of our patients
Figure 2. Kaplan-Meier probabilities of OS, DFS, current thalassemia-
free survival, rejection, and TRM in 25 patients with class III thalassemia.
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for Advanced b-thalassemiaachieved the targeted AUC range after the first dose,
which differs significantly from the results of Vassal
et al. [7], in which 91% of children undergoing SCT
achieved the Bu therapeutic window. Our findings
are more in line with the large interindividual variation
of AUC reported by other authors, in which up to
66% of children being treated for an heterogeneous
group of diseases required Bu dose adjustment
[8-10]. Our study is unique in terms of the homogene-
ity of disease, the severity of pretransplantation organ
dysfunction, and the specific ethnic origin of the pa-
tients. All of these characteristics may have influenced
i.v. Bu PK.
As has been noted previously [16,17], a marked in-
crease in glutathione S-transferase (GST) concentra-
tion in thalassemic patients could be responsible for
the unpredictable Bu PK. GST is the enzyme largelyFigure 3. Kaplan-Meier probabilities of OS, DFS, rejection, and TRM in
28 patients with class I-II thalassemia.responsible for Bu metabolism, and its activity is in-
versely correlated to Bu plasma concentration. Iron
overload might induce GST via activation of the
Nrvf2/keap1 pathway [17], thereby facilitating the
conjugation of Bu to glutathione. In addition, abnor-
mal liver function per se might affect Bu clearance
and RRT, as suggested by studies finding an associa-
tion between elevated serum ALT level and reduced
Bu clearance [18]. Finally, GST-A1 isoforms are
known to be distributed evenly in Caucasians, African
Americans, and Hispanics [19,20]. As has been
suggested previously [20], GST polymorphisms in
different ethnic groups might affect Bu PK unpredict-
ability. As has been reported for oral Bu [21], we found
no clear correlation between the severity of specific
clinical features (ie, Pesaro risk stratification, degree
of iron overload or portal fibrosis, transaminase level,
age, or presence of viral hepatitis) and Bu underexpo-
sure or overexposure. However, we speculate that for
the aforementioned reasons, our series of patients
with advanced b-thalassemia and severe liver disease
demonstrated erratic and unpredictable Bu clearance.
Lack of efficacy or RRT was not correlated with Bu
AUC, most likely because of the Bu dose-adjustment
policy.
In this series, the ablative conditioning based on
targeted i.v. Bu translated into a high engraftment
rate with low TRM and RRT despite the presence of
clinical features of advanced disease. The mortality
rate (4%) compared favorably to rates reported with
oral Bu in children affected by hemoglobinopathies,
including 12% in a recent update by Lucarelli and
Gaziev [4], 8.7% by Di Bartolomeo et al. [22], and
5.4% by Lawson et al. [23]. TRM also was comparable
to that seen in children with b-thalassemia treated with
a treosulfan-based regimen with the aim of minimizing
Bu-related toxicity [24]. The incidences of grade II-IV
aGVHD and cGVHDwere low (13% and 8%, respec-
tively). Only 2 patients experienced grade III stomati-
tis, and only 1 patient (2%) developed reversible VOD.
Targeted i.v. Bu and prophylactic defibrotide likely
served as protective cofactors in this high-risk popula-
tion. Defibrotide also may have contributed to low
RRT andGVHD, as suggested by a recent multicenter
trial [25]. Eight children presented with primary or
secondary engraftment failure, resulting in an overall
thalassemia-free survival of 79%. Four children under-
went a second SCT and achieved complete and sus-
tained donor engraftment, increasing the current
thalassemia-free survival to 88%. A second SCT with
another round of i.v. Bu conditioning was feasible
and well tolerated without major organ toxicity [13].
Unfortunately, the application of a Bu dose-adjust-
ment policy and intensive immunosuppression with
steroids, CsA, and ATG did not resolve the problem
of rejection in patients with advanced thalassemia.
The rejection rate in patients with advanced disease
628 Biol Blood Marrow Transplant 16:622-628, 2010R. Chiesa et al.was high and in accord with that reported by Lucarelli
and Gaziev [4] and by others in related [22,23] and
unrelated donor SCTs [26]. We speculate that this
population’s poor socioeconomic background contrib-
uted to the increased risk of graft failure. Indirect evi-
dence of strong alloimmunity was provided by the
detection of high numbers of anti-HLA antibodies in
all class III patients, as a result of chronic transfusions
with non–leuko-depleted blood products. The addi-
tion of ATG to the regimen for class III patients after
3 graft failures in the first 6 patients treated was thus
intended to facilitate a state of mutual tolerance be-
tween donor and recipient; however, this strategy
failed to resolve the problem of rejection, with graft
failure occurring in 4 of the 18 patients who subse-
quently underwent SCT.
In summary, our results indicate that an i.v.
Bu-based conditioning regimen can be applied to
a high-risk group of thalassemic patients with poor
pretransplantation clinical conditions, but, because of
unpredictable PK, therapeutic drug monitoring is
strongly recommended to minimize the risk of RRT
or lack of efficacy. These results may be taken into con-
sideration for health care policy discussions in Middle
Eastern countries in which implementation of trans-
plantation programs is ongoing.
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